参考文献: [1]Whang, Jennifer A.; Chang, Betty Y. (2014). Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. Drug Discovery Today. doi:10.1016/j.drudis.2014.03.021 [2]Gayko, U., et al., Development o...
参考文献: [1]Whang, Jennifer A.; Chang, Betty Y. (2014). Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. Drug Discovery Today. doi:10.1016/j.drudis.2014.03.021 [2]Gayko, U., et al., Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B c...
4. The role of Bruton’s Tyrosine Kinase in the immune system and disease. Immunology 2021, 164, 722–736. 5. Bruton’s Kinase Inhibitors for the T reatment of Immunological Diseases. . J. Clin. Med. 2022, 11,280...
参考文献: [1]Whang, Jennifer A.; Chang, Betty Y. (2014). Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. Drug Discovery Today. doi:10.1016/j.drudis.2014.03.021 [2]Gayko, U., et al., Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B c...
for inflammatory immune responses such as autoimmune diseases and allergies. This review provides an overview of the mechanisms by which BTK contributes to immune-related diseases and summarizes current research on the development of BTK inhibitors for ...
Btk inhibitors (inhibiting targets of signaling pathways) used for various assays, some have entered clinical trials, which would be new cancer therapies.
1.Tingyu Wen1,Jinsong Wang,Yuankai Shi1,Haili Qian,Peng Liu, Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances, Leukemia (2021) 35:312–332 2.Philip A. Thompson and Constantine S. Tam, Pirtobrutinib: a new hope for patients with BTK inhibitor–refractory...
BTK Inhibitors Provide Extensive Frontline Treatment Options in Treatment-Naïve CLL Seema A. Bhat, MD, discussed the case of 61-year-old patient with chronic lymphocytic leukemia during a Targeted Oncology Case-Based Roundtable event. Seema A. Bhat, MD, assistant professor of Medicine, ...
[1]Whang, Jennifer A.; Chang, Betty Y. (2014). Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. Drug Discovery Today. doi:10.1016/j.drudis.2014.03.021 [2]Gayko, U., et al., Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignan...
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are current standard of care for patients with EGFR mutation and metastatic non-small-cell lung carcinoma (NSCLC), but most patients using EGFR TKIs acquire resistance later. So, overcoming resistance of EGFR TKIs has become...